Silo Pharma has entered into a non-binding Letter of Intent (LOI) with Allucent (US) to provide clinical research services for two planned phase I studies evaluating its SPC-15 nasal spray in healthy subjects: an open-label, Single Ascending Dose (SAD) study and an open-label, Multiple Ascending Dose (MAD) study.

Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order to cover a comprehensive scope of activities across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling and simulation, and medical writing to support execution and reporting of the phase I programme. The LOI also outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs that would be reconciled against final project invoices.

“This Letter of Intent with Allucent could lead to a meaningful step forward in advancing SPC-15 into phase I clinical development. Their global CRO expertise and integrated clinical capabilities appear to align well with our goal of efficiently generating high-quality safety and pharmacokinetic data. We believe this collaboration will allow us to execute our SAD and MAD studies with rigour and speed. Advancing SPC-15 remains a key priority as we strive to build long-term value across our pipeline,” said Eric Weisblum, Chief Executive Officer, Silo Pharma.